Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing a cyclodextrin
Tag: Niemann Pick Disease
Treatment of Niemann-Pick Disease Type C using crosslinked 2-hydroxypropyl-β-cyclodextrin
Niemann-Pick Disease Type C (NPC) is a severe neurovisceral disorder that is pathophysiologically characterized by intracellular transport abnormalities leading to
Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Potential COVID-19 therapeutics from a rare disease: utilization of lipid dysregulation to combat viral infectivity
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
Cyclo Therapeutics reports international patent application for treating Alzheimer’s
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.
pH-Responsive Polymersome Microparticles as Smart Cyclodextrin-Releasing Agents
A paper has recently come out open-access in Biomacromolecules reporting on pH-Responsive Polymersome Microparticles as Smart Cyclodextrin-Releasing Agents (DOI: 10.1021/acs.biomac.9b01083).
Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
HPBCD is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease
Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin
National Niemann Pick Disease Family Conference
The annual National Niemann Pick Disease Family Conference will be held on August 15-18, 2019, in Bloomington, US. The conference